Lyra Therapeutics (LYRA) Tops Q3 EPS by 5c

Lyra Therapeutics (NASDAQ: LYRA) reported Q3 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $544 thousand versus the consensus estimate of $281.6 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Largo restructures $82.2M in debt, extending maturity to 2030
• Citi cuts Weibo stock rating to Neutral, lowers price target